Q2 2022

Filed Aug 9, 2022 · 10-Q · 40 days after period end · 0001410578-22-002177

Q2 2022 · 10-Q

Revenue

$477.00K

+14.7% vs Q2 2021

Net Income

-$29.67M

N/M vs Q2 2021

EPS Diluted

-$0.01

N/M vs Q2 2021

Operating Income-$21,099,000N/M

Operating Cash Flow

Same quarter

Metric	Q2 2022	Q2 2021	Q2 2020	Q2 2019
Revenue	$477.00K	$416.00K	$2.00K	$581.00K
Net Income	-$29.67M	$4.41M	-$57.95M	$219.00K
EPS Diluted	-$0.01	-$0.01	-$0.08	$0.00

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Northwest Biotherapeutics Inc · CIK 1072379 · Engraved from SEC EDGAR